秘鲁患者VKORC1与CYP2C9基因多态性与华法林维持剂量的关联
结果显示VKORC1 AA基因型与较低华法林维持剂量相关,而CYP2C9多态性与剂量无显著关联。
要点
- VKORC1 AA基因型患者华法林周剂量显著低于GA和GG型。
- CYP2C9基因多态性与华法林维持剂量无显著关联。
- 秘鲁人群VKORC1基因型分布以GG型最常见。
核心结论
- VKORC1基因AA基因型与秘鲁患者较低华法林维持剂量相关。
- CYP2C9基因多态性与华法林剂量无显著关联。
研究设计与样本
- 纳入标准:抗凝>3个月、至少3次门诊维持稳定剂量、INR在2.5-3.5治疗范围内。
- 采用非概率便利抽样,外周血DNA用于基因分析。
主要发现
- 患者平均年龄69.6±13.4岁,女性45.7%,平均周华法林剂量31.6±15.2 mg。
- VKORC1基因型频率:AA 7.1%(95%CI 2.4-15.9),GA 44.3%(32.4-56.7),GG 48.6%(36.4-60.8)。
- CYP2C9基因型频率:CC(*1/*1)82.8%(72.0-90.8),CT(*1/*2)4.3%(1.0-12.0),TT(*2/*2)12.9%(6.1-23.0)。
- CYP2C9基因多态性与华法林剂量无显著关联。
临床怎么用
- 对于秘鲁患者,VKORC1 AA基因型可提示需较低华法林维持剂量。
- CYP2C9基因型检测在该人群中未显示剂量预测价值。
局限性
- 仅纳入秘鲁单一中心门诊患者,外推性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to investigate the association between VKORC1 and CYP2C9 genes polymorphisms and the maintenance dose of warfarin in Peruvian patients. METHODS: An observational study was conducted on outpatients from the Hospital Grau ESSALUD in Lima, Peru. The participants were selected using nonprobabilistic convenience sampling. Inclusion criteria required patients to have been on anticoagulation therapy for >3 months, maintain stable doses of warfarin (consistent dose for at least 3 outpatient visits), and maintain an international normalized ratio within the therapeutic range of 2.5-3.5. DNA samples were obtained from peripheral blood for gene analysis. RESULTS: Seventy patients (mean age of 69.6 ± 13.4 years, 45.7% female) were included in the study. The average weekly warfarin dose was 31.6 ± 15.2 mg. The genotypic frequencies of VKORC1 were as follows: 7.1% (95% confidence interval, 2.4-15.9) for AA; 44.3% (32.4-56.7) for GA; and 48.6% (36.4-60.8) for GG. No deviation from the Hardy-Weinberg equilibrium was observed in the variants studied (P = .56). The mean weekly warfarin doses for AA, GA and GG genotypes were 16.5 ± 2.9, 26.5 ± 9.5 and 37.9 ± 17.1 mg, respectively (P < .001). The genotypic frequencies of CYP2C9 were as follows: 82.8% (72.0-90.8) for CC (*1/*1); 4.3% (1.0-12.0) for CT (*1/*2); and 12.9% (6.1-23.0) for TT (*2/*2). We did not find a significant association between the CYP2C9 gene polymorphism and the dose of warfarin. CONCLUSIONS: The AA genotype of the VKORC1 gene was associated with a lower maintenance dose of warfarin in Peruvian patients.
引用
- Oscanoa TJ, Guevara-Fujita ML, Fujita RM, et al. Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients. Br J Clin Pharmacol. 2023. PMID: 37940132. doi:10.1111/bcp.15958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。